AmCham EU has highlighted the need for: investment in holistic healthcare systems which support both patients and care givers and have the resilience to guarantee continuity of care even when faced with a pandemic; modernised healthcare infrastructure which is fit for digitalisation and in particular the need to accelerate the standardisation of electronic health records and the electronic patient dossier for efficiency reasons; policies which support healthy lifestyles; and investment in next generation medical devices and manufacturing processes to provide access to innovative treatments to Europe citizens in the future, including the suggestion of a new mission as part of Horizon Europe focused exclusively on health systems innovation.
Impact of COVID-19 on cancer care and research
AmCham EU provided a response to the open consultation of the BECA (Beating Cancer) Committee of the European Parliament. The consultation addresses the impact of the COVID-19 health crisis on cancer care services and patients. Focusing on both the short- and long-term impacts of COVID-19 the consultation looks at: provision and continuity of care during the pandemic for cancer treatment and screening; lifestyle; the impact on patients and care providers; and related matters on data, research and innovation to improve cancer treatment and healthcare systems in the future. Read our consultation here.
Related items
:focal())
News
20 May 2026
Healthcare, competitiveness, innovation and simplification
Europe’s life sciences sector sits at the heart of the EU’s competitiveness agenda. It supports advanced manufacturing and helps bring new treatments and technologies to patients. Yet companies deciding where to invest need a regulatory environment that is predictable and open to global cooperation.
The European Commission’s work on the Biotech Act and the targeted revision of the Medical Devices and In Vitro Diagnostics Regulations (MDR/IVDR) offers an opportunity to improve that environment. Both files can help make Europe a stronger location for life sciences investment.
The EU should use this moment to build a framework that keeps pace with scientific progress. That means faster and clearer procedures. It also means better use of data and intellectual property rules that recognise the realities of global supply chains.
:focal())
Position Paper
19 May 2026
Strengthening EU competitiveness through an adaptive MDR/IVDR framework
Position Paper
19 May 2026
A global approach to strengthening Europe’s biotechnology ecosystem
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.